The dawn of China biopharma innovation

McKinsey & Company

Chinese biopharma is making a mark on the global stage as the rapidly evolving regulatory landscape and maturing innovation ecosystem spur significant value creation.

Integrated evidence generation: A paradigm shift in biopharma

McKinsey & Company

Biopharma companies should consider a new, integrated approach to evidence-generation strategies to better demonstrate the value of therapies to all stakeholders.


Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Leveraging digital and analytics in biopharma operations: Six principles

McKinsey & Company

To maximize its benefits, biopharma companies can follow six principles. Digital and analytics is a powerful tool for transforming operational performance. Insights on Operations Analytics Operations

Biopharma 2020: A landmark year and a reset for the future

McKinsey & Company

Biopharma in 2020 has shown what it can achieve when it works at its best. How can the industry build on this renewed sense of purpose in the years ahead? Insights on Pharmaceuticals & Medical Products

Reflections on 2020 ASAP BioPharma Conference: The right mindset is more important than ever

Vantage Partners

Overview The 2020 ASAP BioPharma conference came to a close a month ago and marked another year of bringing together talented and thoughtful strategic alliance professionals to share and reflect on their experiences in this field.

O’Dwyer’s PR News: “The Biopharma Communications Balancing Act”

LaVoie Health Science Blog

The post O’Dwyer’s PR News: “The Biopharma Communications Balancing Act” appeared first on LaVoie Health Science. LaVoieHealthScience President and CEO, Donna LaVoie , contributed to the O’Dwyer’s PR News Magazine October issue focused on healthcare and medical public relations.

Life Sciences’ Contribution to the US Digital Therapeutics Market to Grow the Fastest amongst all End Users

Frost & Sullivan

Over the next two to three years, biopharma companies also will highly invest in DTx solutions, enabling the subsidized cost to patients in exchange for marketing and access to patient data.

Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe

Frost & Sullivan

Healthcare News Press Releases biopharma biopharmaceutical biotechnology biotherapeutics COVID-19 vaccine logistics DNA drug mrna pharma Pharmaceutical research RNA therapeutics vaccine

Discover Six Dynamic Trends to Disrupt the Next Generation of Biopharmaceutical Manufacturing

Frost & Sullivan

Healthcare News Press Releases White Papers Analytics biopharma biopharmaceutical chemistry Manufacturing technology therapies

Optimizing Your Alliance Management Operating Model: Considerations from CHI's 2020 Strategic Alliance Management Congress

Vantage Partners

As in the past, this conference featured insightful presentations from leaders across Biopharma alliance management. Vantage Partners was proud to be the premier sponsor for Cambridge HealthTech Institute’s (CHI) 2020 Strategic Alliance Management Congress.

7 Reasons Why PPD’s Acquisition will Help TMO Gain a Top Spot in the CRO Market

Frost & Sullivan

2 – The consolidation of PPD with TMO’s Patheon manufacturing unit creates a compelling end-to-end offering for biopharma sponsors and an opportunity to cross-sell services through revenue stream synergies.

IEEE-ISTO Announces a New Alliance to Advance Clinical Research Data Sharing


A group of leading BioPharma companies, academic institutions, and non-profit data-sharing platforms have come together to establish the Clinical Research Data Sharing Alliance (CRDSA). PISCATAWAY, N.J.,

LHS Expert Insights: ESG Issues for Life Science Innovators

LaVoie Health Science Blog

What are some of the unique considerations that biopharma and life science firms must consider in mapping out their ESG strategies? Certainly few industries have received more scrutiny over the past year than biopharma.

2021 Preview: A 360-Degree Global Market View

LaVoie Health Science Blog

Panelists, including myself as moderator, consisted of industry leaders, including Dr. Alexandra Goll, Managing Director of Biopharma Advisory; Brad Loncar, CEO of Loncar Investments; and Amit Munshi, President, CEO and Board Member of Arena Pharmaceuticals.

Technology Innovations and Virtual Consultations Drive the Healthcare Industry Transformation by 2025

Frost & Sullivan

Biopharma companies should partner with niche AI and data vendors to expedite drug design and development to reduce internal R&D risks for personalized therapies. Global healthcare revenues in 2025 will exceed $2.6 trillion propelled by AI and telehealth, finds Frost & Sullivan.

Technology Investments will Help Oncology Practices Succeed in Value-based Care

Frost & Sullivan

Cardinal Health Specialty Solutions is a leading provider of technology and distribution solutions to specialty healthcare practices and biopharma manufacturers. Frost & Sullivan’s latest article highlights steps to transition to an Oncology Care First model. SANTA CLARA, Calif. –

Is the Potential Threat of Shareholder Activism Heightened by the Pandemic?

LaVoie Health Science Blog

And is your company prepared for what may be coming next?